drugset / Trial / NCT06494514
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Irinotecan Sucrosofate | Other / unclassified | — | — |
| Subject | LV | Unknown | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |